Chiesi USA, Inc. — Trimbow (beclomethasone/formoterol/glycopyrrolate)
for maintenance treatment of asthma
FDA approved Trimbow (beclomethasone/formoterol/glycopyrrolate) inhaler for maintenance treatment of asthma.
for maintenance treatment of asthma
FDA approved Trimbow (beclomethasone/formoterol/glycopyrrolate) inhaler for maintenance treatment of asthma.
Asthma is a chronic inflammatory airway disease that causes recurring episodes of wheezing, chest tightness, and shortness of breath due to narrowed airways and excess mucus. Trimbow combines three medications—beclomethasone (an anti-inflammatory steroid), formoterol (a long-acting airway opener), and glycopyrrolate (a muscle relaxant for the lungs)—to target multiple aspects of asthma. Together, they may help control symptoms and improve lung function by reducing inflammation, keeping airways open, and preventing sudden constriction.
Primary objective The primary objective was to evaluate the efficacy of a free combination of CHF 5259 at 3 dose levels plus Foster® 100/6 μg in a pMDI by comparison with Foster® 100/6 μg in terms of forced expiratory volume in the first second (FEV1) area under the curve between time 0 and 12 hours (AUC0-12h) normalised by time on Day 42. Key secondary objective The key secondary objective was to evaluate the efficacy of the free combination CHF 5259 plus Foster® 100/6 μg by comparison wit...
Source: ClinicalTrials.gov